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SUMMARY

We conducted PrediXcan analysis of hydrocephalus risk in ten neurological tissues and whole blood.
Decreased expression of MAEL in the brain was significantly associated (Bonferroni-adjusted p < 0.05)
with hydrocephalus. PrediXcan analysis of brain imaging and genomics data in the independent UK Biobank
(N = 8,428) revealed that MAEL expression in the frontal cortex is associated with white matter and total brain
volumes. Among the top differentially expressed genes in brain, we observed a significant enrichment for
gene-level associations with these structural phenotypes, suggesting an effect on disease risk through regulation of brain structure and integrity. We found additional support for these genes through analysis of the
choroid plexus transcriptome of a murine model of hydrocephalus. Finally, differential protein expression
analysis in patient cerebrospinal fluid recapitulated disease-associated expression changes in neurological
tissues, but not in whole blood. Our findings provide convergent evidence highlighting the importance of tissue-specific pathways and mechanisms in the pathophysiology of hydrocephalus.

INTRODUCTION
Hydrocephalus is a heterogeneous disease resulting from
abnormal accumulation of cerebrospinal fluid (CSF) and subsequent elevations in intracranial pressure resulting in impaired
neurodevelopment and morbidity (Kahle et al., 2016; Tomycz
et al., 2017). Hydrocephalus affects nearly 1 in 1,000 babies
born in the United States (Simon et al., 2008), yet the genetic basis of the disease is largely unknown (Kousi and Katsanis, 2016).
While clinical trials have attempted pharmacological strategies
to treat hydrocephalus (Whitelaw et al., 2001), no pharmacological approaches have been successful. The current treatments
for hydrocephalus are surgical interventions such as insertion
of a ventriculoperitoneal (VP) shunt as well as endoscopic third
ventriculostomy (ETV) with or without choroid plexus cauterization (CPC) (Kahle et al., 2016; Kulkarni et al., 2017). While many
studies have evaluated the efficacy and cost of these procedures (Lim et al., 2018), long-term morbidity remains high.
Hydrocephalus can be a secondary consequence of intraventricular hemorrhage (IVH), spina bifida, infection, brain tumor, or
congenital form. In addition, anatomic obstruction (i.e., aqueductal

stenosis) impairing the flow of CSF can be caused by a rare
X-linked mutation in L1 cell adhesion molecule (L1CAM) (Rosenthal et al., 1992). Proposed pathophysiological mechanisms of hydrocephalus include impaired development of the neural stem cell
niche (Furey et al., 2018; Lehtinen et al., 2011, 2013; Lehtinen and
Walsh, 2011; Carter et al., 2012), abnormal ciliated ependymal
cells (Takagishi et al., 2017; Wilson et al., 2010; Wodarczyk
et al., 2009), disruption of the ventricular zone (Castaneyra-Ruiz
et al., 2018; McAllister et al., 2017), and dysfunction of CSF absorption and/or secretion (Karimy et al., 2017; Lun et al., 2015b).
However, very little is known about the underlying germline genetic
contributions to hydrocephalus (Kousi and Katsanis, 2016; Zhang
et al., 2006).
While numerous studies have sought to identify causative genetic mechanisms leading to hydrocephalus, largely based on
isolated human case studies and murine models (Kousi and Katsanis, 2016), critical limitations include cost, patient/family
recruitment, number of patients (small by standards of population genetics), individual variant validation (typically de novo mutations), and very important species differences between model
organisms and human disease. As hydrocephalus is a
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component of a wide array of genetic syndromes and Mendelian
disorders, as well as a secondary consequence of many pathologies, we hypothesized that hydrocephalus is a polygenic and
complex disease, but may converge on a limited number of pathways. Thus, elucidation of the genetic basis of hydrocephalus
may lead to new insights into pathophysiological mechanisms
and identification of targets for pharmacological intervention.
Genome-wide association studies (GWASs) have become
ubiquitous as a tool for identifying genetic predispositions to
complex traits, but these analyses require very large sample
sizes. Importantly, the underlying mechanisms for the identified
loci are, for the most part, unclear. Elucidating the mechanistic
basis of a complex, polygenic disorder (Manolio et al., 2009) requires understanding the molecular events that give rise to the
disease process. We hypothesized that the summative risk for
hydrocephalus results from small variation in the expression of
many genes, leading to alterations of a limited number of pathways or biological processes that ultimately predispose individuals to disease. Because of the unavoidably smaller sample size
for hydrocephalus (relative to other complex disorders), we
aimed to test genes whose expression can be reliably determined using genetic variation (rather than millions of genetic variants, as in conventional GWASs, with unknown gene targets) in
order to substantially improve statistical power.
To this end, we used whole-genome genetic data (from blood
collected for routine clinical care) linked to the deidentified electronic medical record (BioVU; Roden et al., 2008) to perform the
largest genetic analysis of hydrocephalus to date. We hypothesized that genetically determined gene expression contributes
to the development of hydrocephalus. Thus, we applied PrediXcan (Gamazon et al., 2015), a gene-based method that utilizes
the genetic component of gene expression for disease gene
identification, leveraging imputation models derived from a
reference human transcriptome panel of neurological tissues
(10 brain regions from 889 individuals) and whole blood (from
338 patients) (Battle et al., 2017). Our approach identified
genetically determined gene expression traits and pathways
associated with hydrocephalus. Although correlation does not
imply causation, a disease association with genetically determined expression substantially improves on a SNP-based association from conventional GWASs (in which the relevant
gene is generally unknown; Nicolae et al., 2010). We considered
whether the gene-level associations were driven by linkage
disequilibrium (LD) contamination. We observed a notable degree of tissue specificity in the association of genetically determined gene expression with hydrocephalus risk. We replicated
our experiment-wide significant finding in an independent
GWAS dataset (UK Biobank) (Bycroft et al., 2018). Furthermore,
we sought functional support for our findings using PrediXcan
analysis of imaging-based phenotypes in the UK Biobank (Elliott
et al., 2018) and transcriptome analysis of a murine model of hydrocephalus. Finally, we compared protein expression analysis
from CSF isolated from infants with hydrocephalus to gene
expression changes identified by PrediXcan, mirroring our findings in neurological tissues, but not in whole blood. In sum, we
illuminate the complex genetic architecture of hydrocephalus
and offer crucial insights into the pathophysiological basis of
the disease.
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RESULTS
A diagram illustrating our study design and approach can be
found in Figure 1. In this study, we performed a systematic genetic study of hydrocephalus using PrediXcan (Gamazon et al.,
2015, 2018), a methodology that estimates the genetic component of gene expression, to identify gene-level associations
with disease. We performed systematic validation of our genetic
findings using independent replication in the UK Biobank, analysis of brain structural imaging phenotypes linked to genetic information in the UK Biobank, transcriptome analysis of choroid
plexus isolated from a murine model of hydrocephalus, and
comparison of genetically determined expression changes to
directly measured differential proteomic expression analysis of
CSF isolated from infants with hydrocephalus.
Generation of imputed transcriptome (PrediXcan) to
identify hydrocephalus-associated genes
Estimation of the genetically determined transcriptome in 10
neurological tissues and whole blood was performed using PrediXcan (Figure 1; see STAR Methods). Differential expression
analysis in the frontal cortex highlighted maelstrom spermatogenic transposon silencer (MAEL) and lysine demethylase 1A
(KDM1A) as outliers (Figure 2A). After multiple testing correction
(Benjamini-Hochberg adjusted p < 0.05), MAEL, but not
KDM1A, in the frontal cortex was significantly associated with hydrocephalus (Figure 2B). Notably, MAEL was experiment-wide
significant, satisfying a highly stringent Bonferroni threshold for
statistical significance (pBonferroni < 0.05) based on the total number of gene-tissue pairs tested (see STAR Methods). We note that
the p value threshold for significance for PrediXcan is not the same
as that for traditional GWAS, with PrediXcan enjoying a substantially reduced multiple testing burden (Gamazon et al., 2015; see
STAR Methods). Genetically determined MAEL expression did
not differ between varying etiologies of hydrocephalus (i.e., idiopathic congenital, neural tube defects, and others), and the
MAEL association was not specific to any one specific etiology.
Finally, as a Manhattan plot illustrates, MAEL was uniquely associated with hydrocephalus within the locus and across all genes
tested in the frontal cortex (Figure 2C), suggesting that the
MAEL association was not merely the result of LD with a different
causal gene within the locus. The MAEL association was also
observed in the hypothalamus (Figures 2D–2F), based on the total
number of genes tested in this tissue. In both frontal cortex and hypothalamus, decreased expression of MAEL conferred increased
predisposition to hydrocephalus. A complete list of all SNPs (and
their relative weights) in the MAEL cis region (i.e., within 1 Mb)
included in the PrediXcan models for frontal cortex and hypothalamus are included in Table S1.
Interestingly, gene expression differences between cases and
controls in whole blood, the tissue most often acquired for human
genetics studies due to easy accessibility and low cost, showed no
significant departure from null expectation (Figures 2G–2I) despite
its much larger sample size and, hence, statistical power, demonstrating the importance of considering tissue-specific expression
differences in relevant tissues when performing genetic screens
of hydrocephalus. However, whole-blood analysis revealed nominally significant associations with previously reported candidate
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Figure 1. Overview of our approach
We leverage a large DNA biobank, BioVU (Roden et al., 2008), linked to deidentified electronic health record (EHR) data. We applied PrediXcan (Gamazon et al.,
2015, 2018), which estimates the tissue-specific, genetically determined component of gene expression (i.e., the ‘‘germline genetic profile’’ of the gene
expression trait) based on common variants (minor allele frequency >1%) and imputation against a reference transcriptome panel. For this study, we used GTEx
transcriptome data in 10 neurological tissues and whole blood (Battle et al., 2017). The genetic component of expression was then tested for association with
phenotype to identify gene-level associations. We performed systematic validation using independent replication of genetic results in the UK Biobank (Bycroft
et al., 2018), analysis of structural brain magnetic resonance imaging (MRI) phenotypes in the UK Biobank (Elliott et al., 2018), and analysis of choroid plexus
isolated from a mouse model of hydrocephalus (Robledo et al., 2008) and compared genetically determined gene expression changes to proteomic analysis of
cerebrospinal fluid (CSF) isolated from infants with hydrocephalus compared to non-affected controls. A summary of each phenotype and the corresponding
sample size can be found in Table S4.

genes—CCDC28A (Cardenas-Rodriguez et al., 2013), MARCKS
(Chen et al., 1996; Lang et al., 2006), and TNFRSF10D (Habiyaremye et al., 2017; Jiménez et al., 2014)—that have been independently implicated in human and mouse studies of hydrocephalus.
The list of genes nominally associated (p < 0.05) with hydrocephalus disease status and the distribution of association p
values varied across neurological tissues (Figure 3A; Data S1).
Gene expression differences between cases and controls in the
frontal cortex were the most significant (Figure 3A). The distribution
of gene effect sizes on hydrocephalus differed across neurological
tissues (Figure 3B), highlighting the importance of examining tissue-specific effects on disease risk in neurological tissues. We
performed hierarchical clustering of nominally associated genes

across neurological tissues (Figure 3C). Using multiscale bootstrap resampling (with ‘‘average’’ as the agglomerative method,
‘‘correlation’’ as distance method, and 1,000 bootstrap replicates;
Shimodaira, 2004), we found that, in contrast to the genes nominally associated with hydrocephalus (p < 0.05), randomly sampled
genes did not lead to stable clusters, i.e., the hypothesis ‘‘the cluster does not exist’’ cannot be rejected at the significance level of
0.05 (with an ‘‘approximately unbiased’’ value of zero), and do
not recapitulate known relationships between Genotype-Tissue
Expression (GTEx) tissues (between the cerebellar hemisphere
and cerebellum and between the frontal cortex and cortex) (Battle
et al., 2017). The gene-level associations (nominal p < 0.05) are
highly tissue-specific, with the majority detected in one tissue
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Figure 2. Genome-wide scan identifies tissue-specific gene-level associations with hydrocephalus
(A) Volcano plot showing odds ratio (OR, x axis) versus log (p value, y axis) for gene expression differences between cases and controls in the frontal cortex.
(B) Q-Q plot demonstrating a significant association between MAEL and hydrocephalus after correction using Benjamini-Hochberg FDR in the frontal cortex.
MAEL is study-wide significant (adjusted p < 0.05) after Bonferroni adjustment for the number of gene-tissue pairs tested in the study.
(C) Manhattan plot showing the gene-level association p values and chromosomal location of the signal from MAEL in the frontal cortex. The experiment-wide
significant gene MAEL is also the unique gene in the cis region with a nominal gene-level association (p < 0.05) with hydrocephalus.
(D–I) Analogous analyses were performed in hypothalamus tissue (D–F) and whole blood (G–I).
See also Data S1.

(Figure 3D). We provide a list of all nominally significant (p < 0.05)
genes in neurological tissues for reference (Data S1).
Contrary to MAEL’s most commonly studied role in spermatogenesis, MAEL is actually expressed in both males and females,
albeit absent in female sex organs, and is highest in the frontal
cortex (the neurological tissue deviating the most from null
expectation, Figure 1), outside of the testis (Figure 4A). Interestingly, MAEL-deficient mice have been generated, but they do not
develop hydrocephalus (Soper et al., 2008). However, since
MAEL expression is one of the most highly tissue-specific genes
(in expression profile) in the genome (Figure 4B; see STAR
Methods) and because MAEL function differs substantially
across species (Chen et al., 2015), further mechanistic validation
of MAEL in hydrocephalus needs to be performed specifically on
human neurological tissue samples, building on our results from
human GWASs.
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Since the experiment-wide significant genetic signal to
emerge from our analyses was decreased expression of
MAEL in the frontal cortex, we present the canonical model
for MAEL function (Figure 4C). MAEL is a critical regulator of
PIWI-interacting RNA (piRNA)-mediated repression of transposable elements and methylation (Soper et al., 2008). Thus,
decreased MAEL leads to increased transposon mobilization
and differential methylation patterns, leading to broad changes
in gene expression. However, the specific genes in the brain
targeted by MAEL-mediated transposon movement and histone modification H3K9me3, which plays a role in targeting
DNA methylation (Lehnertz et al., 2003), are unknown. Thus,
our study implicates transposon and histone modification (trimethylation) in the pathophysiology of hydrocephalus; however, additional molecular studies are needed to confirm this
finding.
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Replication in the UK Biobank
Applying PrediXcan to brain magnetic resonance imaging (MRI)
white matter and total brain volume data in the UK Biobank (Elliott et al., 2018; Miller et al., 2016) (N = 8,428; see STAR
Methods), we found that MAEL expression in the frontal cortex
was significantly associated with white matter volume (p =
0.011) and total brain volume (p = 0.015) at Bonferroni-adjusted
p < 0.05. Various structural brain alterations have been implicated in the pathophysiology of hydrocephalus (Del Bigio,
2010). Remarkably, we found a significant enrichment for
gene-level associations with white matter (Figure 5A) and total
brain volume (Figure 5B) among the top differentially expressed
genes (p < 0.05) in frontal cortex.
For additional support, we analyzed SNPs within the MAEL cis
region (i.e., the MAEL locus that is used in PrediXcan analysis)
and their association with hydrocephalus in the UK Biobank.
We conducted extensive quality control (QC) on the SNPs within
the locus and excluded all low-confidence variants (see STAR
Methods). We identified nine variants, in LD (r2 > 0.70), nominally
associated with hydrocephalus (p < 0.05, Table S2). The most
significant SNP (rs75008967) overlaps an enhancer element in
fetal brain (male and female) and in several brain regions (Figure S1, H3K27ac) (Creyghton et al., 2010), including hippocampus, substantia nigra, anterior caudate, cingulate gyrus, and
dorsolateral prefrontal cortex, based on Roadmap chromatin
immunoprecipitation sequencing (ChIP-seq) data (Ward and Kellis, 2012). In addition, a variant in the cis region of MAEL
(rs72687818), independent of the lead SNP above (r2 <
0.20), was the most significant association with a common cause
of hydrocephalus, namely ‘‘subarachnoid hemorrhage from

Figure 3. Differentially expressed genes in
neurological tissues and whole blood
(A) Gene-level associations (PrediXcan) with hydrocephalus status, determined by logistic
regression (with sex and age and the genotypebased principal components as covariates), in
each neurological tissue and whole blood,
including genes that depart from null expectation.
MAEL expression in frontal cortex was experiment-wide significant (Bonferroni-adjusted p <
0.05) across all tissue-gene pairs tested.
(B) Significance and effect size of gene-level associations in neurological tissues identifying outliers. Gene associations within each neurological
tissue are color coded.
(C) Hierarchical gene clustering of the nominally
significant gene-level associations (p < 0.05), with
whole blood an outlier relative to the neurological
tissues.
(D) Number of tissues in which gene-level nominal
associations (p < 0.05) with hydrocephalus are
detected.
See also Data S1.

intracranial artery’’ (Germanwala et al.,
2010; Graff-Radford et al., 1989) in the
UK Biobank (p = 1.1 3 10 20). We evaluated the gene-level significance from the
SNP-level association results in the cis region with hydrocephalus (p = 0.03) and with subarachnoid hemorrhage (p = 4.77 3 10 12), strongly confirming the discovery
signal. Collectively, these results provide robust support to the
importance of the MAEL locus for hydrocephalus predisposition.
MAEL-mediated associations with hydrocephalusrelated neurological traits
To explore how genetically determined expression of MAEL may
exert its phenotypic effect on hydrocephalus predisposition in
these specific neurological tissues, we identified a cohort of patients in BioVU with related neurological traits that may facilitate
further insights into hydrocephalus pathophysiology (see STAR
Methods). Consistent with the hydrocephalus associations,
decreased MAEL expression in frontal cortex and hypothalamus
was found to be associated with ‘‘cerebral edema and compression of brain’’ (p = 0.0021 in frontal cortex and p = 0.0018 in
hypothalamus), ‘‘other cerebral degenerations’’ (p = 0.0009 in
frontal cortex and p = 0.001 in hypothalamus), and intracerebral
hemorrhage (p = 0.016 in frontal cortex and p = 0.021 in hypothalamus). These data are consistent with the association of
MAEL expression with regulation of white matter and total brain
volumes obtained through analysis of brain MRI phenotypes
linked to genetic information (Figure 5) in the independent UK
Biobank.
In addition, STRING analysis (version 10.5; Szklarczyk et al.,
2017) revealed a number of direct interacting partners that
may play a role in MAEL-mediated hydrocephalus pathophysiology, offering insights into potential targets for intervention
(Figure S2A). Notably, the other genes in the proposed biological network from the STRING analysis showed nominally
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Figure 4. MAEL expression profile and model of MAEL-mediated trait effect
(A) Population-based expression of MAEL in males (blue) and females (red) across 44 tissues included in GTEx. MAEL is most highly expressed in frontal cortex
among brain regions and displays low expression in whole blood. Box edges show interquartile range, whiskers 1.5 3 the interquartile range, and center lines the
median.
(B) Tissue specificity (x axis) as quantified by t (see STAR methods) versus frequency of genes (y axis) across the genome. MAEL is one of the most tissue-specific
genes in the genome (t = 0.997).
(C) Canonical model of MAEL-mediated alteration of transposon movement and depression of H3K9me3, leading to recruitment of RNA polymerase II (RNA Pol II)
and transcription of previously repressed genes.

significant associations with neurological phenotypes (Figure S2B) in BioVU (see STAR Methods), including ‘‘type 2 diabetes with neurological manifestations’’ and ‘‘polyneuropathy
in diabetes for decreased TDRKH expression’’ (p = 7.9 3
10 4 and p = 2.2 3 10 3, respectively) in whole blood and multiple sclerosis for increased DDX4 expression (p = 0.017) in
frontal cortex.
To assess the significance of the observed MAEL-mediated
neurological trait associations, we performed permutation analysis (n = 1,000) that preserves the pairwise (gene-gene) correlation (within each tissue) of the estimated genetic component of
expression (as well as the gene count) among the tested genes.
We observed a significant enrichment (empirical p < 0.001) for
associations with neurological phenotypes among MAEL’s
direct interacting partners. Thus, there may be some shared underlying risk for other neurological disorders in patients with
alteration of MAEL-dependent biological networks, which lends
additional support for (as noted above) further validation studies
specifically in humans to elucidate MAEL’s role in hydrocephalus
risk.
Transcriptome analysis and validation in a murine model
of hydrocephalus
Many laboratories focus on the use of model organisms in studying hydrocephalus for pre-clinical translational studies. Thus, we
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conducted differential expression analysis (see STAR Methods)
of ChIP-based gene expression data from the choroid plexus
of a-adducin knockout mice, which develop hydrocephalus secondary to IVH (Robledo et al., 2008), one of the most common
causes of hydrocephalus. Interestingly, there was a marked degree of concordance in both the genes involved and the direction
of effect between the transcriptome of a-adducin knockout
mouse choroid plexus and tissue-specific gene expression differences observed in our human cohort (Table S2). Although
MAEL was validated in human GWASs but not in this murine
model, this is consistent with the substantial evidence describing
the species and tissue-specificity of MAEL gene expression and
regulation (Chen et al., 2015; Genzor and Bortvin, 2015). Finally,
nominally significant associations for TMEM50B and KCTD21 (in
frontal cortex and hypothalamus) were replicated in mice with a
concordant direction of effect (Table S3).
Genetically determined pathway associations with
hydrocephalus
To probe relevant biological processes and molecular functions,
we utilized the full set of nominally significant associations (p <
0.05) of genetically determined expression with hydrocephalus
in each neurological tissue, across all tissues, and in whole blood
(Data S1). We hypothesized that pathway analysis of nominally
significant genetically determined expression changes (see
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Figure 5. Genomic analysis of brain MRI data
in the independent UK Biobank validates
gene-level associations with hydrocephalus
in the same (significant) discovery tissue
Using PrediXcan analysis of brain imaging and
genomic data, we validated the study-wide significant association of MAEL in frontal cortex (Bonferroni-adjusted replication p < 0.05). We then
considered the associations with the imagingbased phenotypes of the top differentially expressed genes in frontal cortex.
(A) For the hydrocephalus-associated genes (p <
0.05; in red) in the frontal cortex from the BioVU
analysis, the Q-Q plots show the PrediXcan p values
for their association with white matter volume (A)
and total brain volume (B) in the UK Biobank. The
departure from the diagonal line indicates enrichment for gene-level associations with the imagingbased phenotypes among the hydrocephalusassociated genes. For comparison, a Q-Q plot for a
random set of genes (of equal count; in blue) is
included.

STAR methods) would confirm a number of pathways and biological processes previously associated with hydrocephalus,
and identify additional pathways associated with the disease.
This approach is in contrast to conventional approaches for differential expression analysis (which utilize the total, directly
measured gene expression), enabling us to identify ‘‘genetically
determined’’ and potentially ‘‘causative,’’ rather than consequential disease-relevant networks (see Figure 1).
We performed gene set enrichment analysis (GSEA) (Subramanian et al., 2005) using the Molecular Signatures Database
(MSigDB) on nominally significant genetically determined gene
expression changes in the frontal cortex, hypothalamus, whole
blood (Data S2 and S3), and all other neurological tissues individually as well as cross-tissue analysis (Data S2 and S3, which present significantly enriched gene sets at a false discovery rate
[FDR] of <0.05 in each tissue), as has been previously applied
to GWAS data (Wang et al., 2007, 2010). Experiment-wide significant gene sets were identified using Bonferroni correction (p <
2.9 3 10 7) (see STAR Methods). The level of significance for a
gene set is not correlated with the number of genes in the set
(e.g., Spearman correlation p = 0.68 in frontal cortex). Many of
our top gene-level associations were identified in two or more
neurological tissues (Figure S3; Figure 2D; Data S2 and S3).
GSEA/MSigDB (with default options) was performed on the
225 genes that were nominally significant in two or more tissues
as the input set (Data S2 and S3), recapitulating the involvement
of many pathways identified by single-tissue analysis.
Exome scan and functional genomics suggest
potentially pathogenic variants associated with
hydrocephalus
We analyzed exome data for additional support for the role of the
top differentially expressed genes in hydrocephalus risk. To this
end, we tested the nominally significant hydrocephalus-associated genes detected in at least five tissue types (Figure S3;
see STAR Methods) for coding variation effects on disease susceptibility, using a cohort of 29,713 patients (Figure S4A; Data
S4). TMEM50B, which was also supported in our transcriptome

analysis of a murine model of hydrocephalus (Table S3), contains
a rare missense variant (rs34327244 or A139T, minor allele
frequency [MAF] = 0.4% in Europeans [non-Finnish]) with nominally significant association with hydrocephalus (p = 7.4 3 10 3)
(Figure S4B). After Benjamini-Hochberg correction, this association corresponded to a FDR of 11%, warranting additional functional studies given the convergent evidence for the gene.
Interestingly, we found that rs34327244 was associated with
CSF volume (normalized for overall head size) in the independent
UK Biobank (p = 0.016).
In addition, using ChIP-seq data derived from human embryonic stem cells (HUES64) as part of Roadmap Epigenomics
(Leung et al., 2015), we found that A139T disrupts an active or
primed enhancer element marked by monomethylation of histone H3 at lysine 4 (H3K4me1), suggesting a role for the variant
in regulation of transcription. Furthermore, TMEM50B is co-expressed with aquaporin 1 (AQP1) in the frontal cortex
(Figure S4C), and A139T alters a regulatory motif that leads to
differential allelic affinity of the NKx-2 homeodomain containing
transcription factor thyroid transcription factor 1 (TTF1) (Ward
and Kellis, 2012). Since decreased expression of TTF1 leads to
decreased expression of AQP1 in the apical membrane of the
choroid plexus and alteration in CSF formation (Kim et al.,
2007), it is possible that A139T leads to decreased availability
of TTF1 to promote AQP1 expression (Figure S4D), although
additional experimental validation is needed. These studies provide preliminary evidence for aquaporin dysregulation in genetically determined risk for hydrocephalus.
CSF proteomic data from patients with hydrocephalus
mirror PrediXcan results
Next, we analyzed proteomic data from CSF isolated from patients with hydrocephalus secondary to IVH, from a previously
published study (Morales et al., 2012) for mass spectroscopic
analysis (see STAR Methods), and compared the differentially
expressed proteins to the differentially expressed genes identified by PrediXcan. This analysis revealed a significantly greater
overlap between differentially expressed genes in the frontal
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Figure 6. CSF proteomic signature of patients with hydrocephalus recapitulates gene expression associations identified by PrediXcan
(A) Q-Q plot showing significance for three proteins implicated by LC-MS analysis of CSF isolated from patients with hydrocephalus in the association of their
genetically determined expression in the frontal cortex ( log10 p value from the PrediXcan analysis shown on the y axis).
(B) PrediXcan p values in frontal cortex of the proteomic signature from CSF (true) versus the remaining proteins (false), demonstrating greater statistical significance (i.e., lower p value from PrediXcan) for the proteins in the CSF signature in frontal cortex (left, p = 0.04) but not in whole blood (right, p = 0.83). Significance was assessed using a Mann-Whitney U test. Box edges show interquartile range, whiskers 1.5 3 the interquartile range, and center lines the median.

cortex and the proteomic signature identified by liquid chromatography-mass spectrometry (LC-MS) than expected by chance
(enrichment p = 0.016), identifying three proteins that deviate
from null expectation for differential expression in frontal cortex
between cases and controls (Figure 6A). The most significant
of the three proteins, catalase (CAT), showed a 500-fold
decreased expression (p = 1.56 3 10 48) between patients
with hydrocephalus versus controls. CSF protein levels of
ADAM20 and SCUBE1 also showed nominal association with
hydrocephalus (PrediXcan p < 0.05).
The proteomic signature identified in the CSF tended to have
significantly lower (i.e., more statistically significant) p values
from the PrediXcan analysis of frontal cortex (Mann-Whitney U
test, p = 0.04, Figure 6B, left) than the remaining proteins. In
contrast, we observed no significant expression difference between cases and controls in whole blood (Mann-Whitney U
test, p = 0.83, Figure 6B, right) for the proteins identified by
LC-MS, further showing the limitation of whole blood as a substrate for hydrocephalus genetic analyses. Overall, these results
demonstrate that while CSF proteomic analyses may be useful in
identifying biomarkers for prognostic purposes, its use, without
integration of genetic data, as a discovery platform of genetically
determined pathogenic mechanisms is limited.
DISCUSSION
We describe the largest genetic study of hydrocephalus and
identify trait-associated genes and signaling pathways, laying
the groundwork for molecular studies of hydrocephalus. We
report genetically determined contributions to hydrocephalus,
the functional consequences of identified genes on brain structure, the transcriptomic signature of differentially expressed
genes in choroid plexus of a murine model of hydrocephalus,
and hydrocephalus-associated genetically determined expres-
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sion changes for proteins as measured by an unbiased proteomic screen of CSF isolated from patients with hydrocephalus.
The use of genetic information can be used to disentangle
changes in expression that influence disease versus secondary
expression changes as a result of hydrocephalus, a question
that has remained elusive for more than 30 years (Del Bigio,
1989).
PrediXcan imputes the genetic component of gene expression
in tissues from which it is nearly impossible to obtain clinical
samples, such as neurological tissues. We find a remarkable degree of tissue specificity in gene regulation in hydrocephalus.
However, the degree of tissue, cell-type, and single-cell variation
in hydrocephalus has yet to be fully appreciated. While common
variants and de novo mutations have been shown to play a role in
a range of neurodevelopmental disorders, including hydrocephalus (Niemi et al., 2018; Short et al., 2018; Furey et al., 2018), this
study implicates common variant-mediated regulation of tissuespecific gene expression as a potential driver of hydrocephalus.
Our analysis revealed a significant association between differential expression of MAEL and hydrocephalus status. MAEL contains two domains, that is, (1) a high mobility group (HMG)-box
domain and (2) an RNase H-fold domain that lacks catalytic residues conserved in RNA-H nucleases, but it displays singlestranded RNA (ssRNA)-specific endonuclease activity (Genzor
and Bortvin, 2015; Matsumoto et al., 2015). MAEL is essential
for piRNA-mediated transcriptional transposon silencing. Interestingly, transposons are DNA sequences capable of changing
their position in the genome, with the potential to induce mutations, as well as change a cell’s identity and genomic size. Loss
of maelstrom, the MAEL homolog in Drosophila melanogaster,
has been shown to perturb RNA polymerase II recruitment,
nascent RNA output, and steady-state RNA levels of transposons, leading to increased heterochromatin spreading despite
modest changes in H3K9me3 patterns (Sienski et al., 2012),
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which suggests that MAEL may act independently or downstream of H3K9me3. Consistent with this function, we identified
H3K9me3-dependent changes as one of the most significantly
enriched curated gene sets for differentially expressed genes
(between hydrocephalus cases and controls) across neurological
tissues (Data S2 and S3). However, the expression of MAEL is
one of the most tissue-specific in the genome (Figure 4B), and
a human-specific role for MAEL in neurological disorders has
not previously been described. Thus, additional molecular
studies of MAEL in hydrocephalus risk and pathogenesis should
be performed in human neurological tissue.
Epigenetic modification (H3K9me3) underlying the MAEL association with hydrocephalus is supported by mechanistic data
on the role of piRNA biogenesis factor Mili (a target of MAEL) in
mice. Mili-deficient mice demonstrate broad changes in CpG hypomethylation across the genome (Nandi et al., 2016). Extending
this observation, one of the significantly enriched gene sets
(FDR < 0.05) across neurological tissues with hydrocephalus
was alteration in CpG methylation (Data S2 and S3), providing
convergent functional evidence for the potential role of these
pathways in human hydrocephalus. Furthermore, deletion of
PIWI (another piRNA biogenesis factor) inhibits axon regeneration that is dependent on the slicer domain of PIWI, indicating
that post-transcriptional gene silencing may be involved (Kim
et al., 2018). Since loss of MAEL in mice results in selective transposon insertions (Aravin et al., 2008), this is certainly a plausible
mechanism. However, the complete repertoire of cell type-specific transposon insertion sites in humans remains largely unknown (Elbarbary et al., 2016). Furthermore, there is evidence
that transposon elements are enriched in neural stem cells (Upton et al., 2015), a cell type widely hypothesized to be dysfunctional in hydrocephalus.
Collectively, PrediXcan analysis, rare-variant exome scan, a
murine model of hydrocephalus, and genomic analysis of imaging-based brain structural phenotypes justify additional functional follow-up studies on the role of TMEM50B in hydrocephalus. Interestingly, the chromatin state annotation suggests that
A136T (rs34327244) may play a role in transcriptional regulation.
Indeed, ChIP-seq analysis shows that rs34327244 overlaps an
enhancer region that is marked by monomethylation of
H3K4me1. Analysis of transcription factor binding profiles revealed that rs34327244 alters a regulatory motif, resulting in
differential allelic affinity for NKx-2 homeodomain containing
transcription factor TTF1 (Ward and Kellis, 2012). Intriguingly,
AQP1, a critical regulator of CSF formation and intracranial water
movement (Iliff et al., 2012), is a direct transcriptional target of
TTF1, and AQP1 transcript levels are directly correlated with
TTF1 expression (Kim et al., 2007). Remarkably, we discovered
that rs34327244 was associated with normalized CSF volume
in the UK Biobank. These data suggest that in conferring hydrocephalus risk, AQP1 dysregulation may be causative; however,
additional detailed molecular studies are required to definitively
clarify the role of TMEM50B in tissue-specific AQP1 regulation
and hydrocephalus pathophysiology. Nonetheless, our findings
suggest that integrated analysis of brain imaging and functional
genomics (human and model organism) data can be used to
identify a previously inaccessible molecular mechanism relevant
to hydrocephalus pathophysiology.
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Several functional and structural features on brain MRI have
been associated with hydrocephalus (Del Bigio, 2010); however,
the genetic basis for these observations is not known. A repository
of brain imaging phenotypes from 8,428 individuals tied to GWAS
data in the UK Biobank provides a unique resource to probe these
questions (Elliott et al., 2018). Since CSF, white matter, and total
brain volumes have been independently associated with hydrocephalus (Mandell et al., 2015), we considered the differentially
expressed genes in the frontal cortex identified by PrediXcan (Figures 2A–2C; Data S1) and their PrediXcan associations with these
imaging-derived traits. We observed a significant enrichment for
top associations with these brain structural phenotypes among
the hydrocephalus-associated genes. Testing the effect of hydrocephalus-associated genes on brain-imaging traits may be relevant to understanding both normative brain development and
neurocognitive outcomes in hydrocephalus (Mandell et al.,
2010, 2015; Peterson et al., 2018). Specifically for the aims of
our study, understanding the role of these genes in conferring a
risk for increased (e.g., macrocephaly) and decreased (e.g., cerebral degeneration) brain volume enhances our mechanistic understanding of hydrocephalus risk, as brain volume influences CSF
circulation (Brinker et al., 2014). Alterations in white matter volume
have also been observed in congenital hydrocephalus (Lockwood
Estrin et al., 2016), suggesting a shared genetic component.
Collectively, our data suggest that hydrocephalus-associated
genes may exert their effect on disease risk through their role in
regulating brain structure and integrity.
Human and murine studies have demonstrated the importance
of the CSF proteome in neurodevelopmental disorders as well as
in hydrocephalus. We determined that decreased catalase (CAT)
gene expression in the frontal cortex had a consistent effect on hydrocephalus as decreased CAT protein in the CSF (Figure 6A). The
canonical role of CAT is to cleave hydrogen peroxide into water
and oxygen, an important biological process mediating production of reactive oxygen species. CAT has been shown to regulate
DNA damage, which causes chromosomal aberrations at regions
of the genome centered around transposons (Argueso et al.,
2008). These data provide potential links to chromosomal modifications in hydrocephalus pathophysiology.
CSF-derived signals have been shown to play a major role in
mediating neural tube closure by signaling to the neural stem
cell niche (Chau et al., 2015). In addition, the CSF proteome mediates the localization of Igf1R to the apical membrane of the
choroid plexus, in part through regulation by PTEN (Lehtinen
et al., 2011). Interestingly, CSF from patients with glioblastoma
multiforme (GBM) selectively alters this response (Lehtinen
et al., 2011), suggesting that underlying genetic risk may lead
to selective development of hydrocephalus. Notably, PTEN
signaling is recapitulated here by pathway analysis of genetically
determined expression changes, consistent with previous reports on the role of PTEN/phosphatidylinositol 3-kinase (PI3K)
signaling in hydrocephalus (Kousi and Katsanis, 2016; Yung
et al., 2011; Zheng et al., 2018). Age-dependent alterations in
the CSF proteome can also influence adult neural stem cells
(Silva-Vargas et al., 2016), which could potentially underlie
development of normal pressure hydrocephalus (NPH) in adults.
Interestingly, there is a correlation with neurodegeneration-associated proteins in both CSF and cortical biopsies with NPH,
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suggesting some overlapping pathophysiology (Jeppsson et al.,
2016; Leinonen et al., 2012).
It has already been demonstrated that alterations in choroid
plexus gene expression (Lun et al., 2015a) and the neural stem
cell niche (Carter et al., 2012; Furey et al., 2018) play significant
roles in hydrocephalus. The relationship between neuronal and
choroid plexus development, CSF dynamics, and genetic regulation underpin a highly complex physiological system with multiple
modes of regulation (Lun et al., 2015b). Thus, while we were not
able to directly analyze epithelial cells of the choroid plexus and
cells from the neural stem cell niche in the ventricular/subventricular zone from humans, we identified a number of pathways in
those compartments that had previously been associated with hydrocephalus through targeted molecular and genetic studies. For
instance, analysis of genetically determined expression changes
in frontal cortex revealed protein biogenesis as being significantly
associated with hydrocephalus. Notably, regulation of the genes
encoding the protein biosynthetic machine has been shown to
be essential in forebrain development and development of macrocephaly (Chau et al., 2018). These authors showed mechanistic
evidence detailing mTOR and MYC signaling as critical regulators
of forebrain development, recapitulated here through pathway
analysis of genetically determined expression changes (Data S2
and S3). Furthermore, mTOR signaling-mediated regulation of
cilia has been shown to be required for ventricular morphogenesis
(Foerster et al., 2017), further highlighting the potential importance
of mTOR in hydrocephalus.
Our PrediXcan analysis is currently limited to common variantmediated gene expression. However, as our understanding of
the contribution of rare variants to human genetic regulation increases (with the requisite increase in study sample sizes and investment in functional genomic studies in diverse ancestries;
Zhong et al., 2019), so too will our comprehension of genetically
determined expression across the full range of allele frequency
spectrum. Despite this limitation, our analysis of rare variants
in the most differentially expressed genes in several neurological
tissues provides another layer of functional evidence for the
contribution of these genes to disease susceptibility.
Electronic health records linked to DNA biobanks, as vast repositories of disease and medication data, will enable rapid discovery and replication of genetic associations, as UK Biobank
replication studies in this study have provided support for the
role of MAEL in conferring hydrocephalus risk. Finally, validation
studies of the implicated genetic components of gene expression
in related phenotypes—such as the association between
decreased MAEL expression and ‘‘cerebral edema and compression of brain’’ and ‘‘other cerebral degenerations’’ as well as the
significant enrichment for neurological trait associations among
MAEL’s direct interacting partners—may provide additional
mechanistic insights into hydrocephalus pathophysiology.
We present the largest genetic analysis of hydrocephalus and
extensive genomic analyses to identify hydrocephalus-associated genes and pathways. Our study highlights the complexity
of hydrocephalus pathophysiology and the polygenicity of its genetic architecture. We propose transposon-mediated genetic
regulation through MAEL for future mechanistic validation in hydrocephalus. In addition, we identify a potential molecular basis
for the role of aquaporin in hydrocephalus risk, a mechanism
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long hypothesized to be involved in human hydrocephalus. We
integrate PrediXcan analysis of imaging-based structural brain
phenotypes related to hydrocephalus and demonstrate an
enrichment of genes associated with alterations in brain structure and integrity among risk genes. Finally, we observed enrichment for germline-genetic expression changes in neurological
tissues among the differentially expressed proteins in CSF between hydrocephalus patients and controls, demonstrating the
value of our methodology for the discovery and characterization
of the genetic determinants of hydrocephalus.
Limitations of study
We conducted a transcriptome-wide association study (TWAS)
of hydrocephalus in 10 brain regions and whole blood. Among
the top differentially expressed genes in the brain, we observed
an enrichment for gene-level associations with neuroimaging
phenotypes, indicating an effect on disease risk through regulation of brain structure and integrity. The molecular mediators that
underlie the functional and structural brain variability contributing
to disease risk require detailed follow-up studies. Choroid plexus
transcriptome analysis of a murine model of hydrocephalus and
proteomic analysis of CSF isolated from patients provide additional evidence for the top differentially expressed genes that
reach only nominal significance. A larger sample size will
improve the resolution to detect disease-associated genes. In
the present study, the gene MAEL in frontal cortex attained
experiment-wide statistical significance in BioVU with additional
support in the UK Biobank. Future studies should be aimed at
elucidating the underlying molecular mechanism in human tissue
samples, given the high degree of evolutionary divergence for
the gene in the tissues (i.e., neurological) of interest.
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Data and code availability
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
BioVU, one of the largest DNA biobanks tied to an electronic health records database containing 2.6 million unique patient records, is
a genomics resource at Vanderbilt University Medical Center (Roden et al., 2008). Detailed information on the construction, utilization,
ethics and policies of the BioVU resource is described elsewhere (Roden et al., 2008). Per the policies of BioVU, use of these data fall
under non-human subject determination and are approved by the Vanderbilt University IRB (#170502). We leveraged this resource to
identify patients with a diagnosis of communicating hydrocephalus (Phecode: 331.1, https://phewascatalog.org; Denny et al., 2013;
Wei et al., 2017) who have undergone permanent CSF diversion (VP shunt, ETV, or ETV/CPC). In BioVU, we identified patients of
European ancestry (287 patients with hydrocephalus and 18,740 controls).
The median age at first CSF diversion operation (VP shunt, ETV/CPC, or ETV) was 4.1 years [0.46-11.13, interquartile range] and
58% of patients were male. Seventy-four patients (26%) had post-hemorrhagic etiologies of hydrocephalus, whereas 95 (33%) of
patients were diagnosed with idiopathic (congenital) hydrocephalus. Eighty-five patients (29%) of patients were diagnosed with
neural tube defects. The remaining 33 patients (12%) had other etiologies of hydrocephalus (post-infectious, brain tumor, Chiari Malformation Type I and Dandy-Walker syndrome). Control patients had no diagnosis of hydrocephalus or any other neurological or
developmental disorder. Genomic ancestry was quantified using principal components analysis (Price et al., 2010). To avoid potential
confounding due to population stratification (Derks et al., 2017), we performed our genetic analyses only on patients of European
ancestry. We included 3 genotype-based principal components within the European-ancestry dataset as covariates in downstream
analyses (Price et al., 2006).
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Estimating the genetically determined expression
We implemented PrediXcan (Gamazon et al., 2015), a gene-based method that estimates the genetic component of expression using
imputation models derived from the GTEx reference transcriptome panel in 10 neurological tissues (for a total of 889 brain samples),
including frontal cortex and hypothalamus, and whole blood (from 338 individuals, Data S1) (Battle et al., 2017; Gamazon et al., 2018;
Battle et al., 2017). PrediXcan utilizes a patient’s germline genetic profile to estimate the genetic component of gene expression in
target tissues of interest. The weight (beta) from the imputation model and the number of effect alleles Xij at the variant j for individual i
are used to infer the genetic component of gene expression for the ith patient:
X
c
Xij bbj
Gi =
j

To identify genes associated with communicating hydrocephalus, we performed logistic regression with the genetically-determined
expression as independent variable and disease status, with sex and age as covariates. Although the reference transcriptome panel
(GTEx) consists of healthy controls, the genetically-determined expression was tested for association with disease status in the
GWAS (BioVU) samples. PrediXcan seeks to test the effect on disease risk of the genetic component of gene expression (which
is to be distinguished from the disease-altered component). One advantage of the gene-based test is statistical, i.e., the reduced
multiple testing burden compared to conventional (SNP-based) GWAS (5-10M statistical tests) (Gamazon et al., 2015). Another
advantage is the ability to explicitly test a biologically-meaningful mechanism (gene expression regulation), that is known to be
contributory to complex diseases (Gamazon et al., 2018; GTEx Consortium, 2015) versus genetic variants with mostly unknown
gene targets. We emphasize that even if measured gene expression (RNA-seq) is available in the GWAS samples for differential
expression analysis, this in no way negates the importance of estimating (and then testing for association with disease risk) just
the genetic component of gene expression, as PrediXcan aims to do.
Odds ratios were calculated, as in case-control studies, and genes with nominally significant p < 0.05 are reported. Experimentwide significance for a gene association was evaluated using Bonferroni correction for the total number of gene-tissue pairs tested
(n = 9,868) for which expression imputation quality in a tissue (assessed in the reference GTEx panel) satisfied r2 > 0.01. False discovery rate (Benjamini-Hochberg) was set at 0.05 for each tissue.
Tissue specificity of gene expression was quantified using the tau statistic (Kryuchkova-Mostacci and Robinson-Rechavi, 2017)
applied to the GTEx tissues:
t=
where

n
X
1
n
i=1

xbi
1


xbi = xi max x
1%j%n

j

Here, xi provides the expression values for the gene i, and n is the number of tissues.

Genetically determined pathways and networks
Since the heritability of traits that have been interrogated through GWAS has been shown to be enriched for regulatory variation (Gamazon et al., 2018), we hypothesized that using the genetically determined component of gene expression, as quantified through
PrediXcan, rather than the total expression (with potential environmental and technical confounding components) would enhance
statistical power to identify pathophysiologically relevant pathways and networks. For each tissue type, we used as input the genes
whose genetic component showed nominal association (p < 0.05) with hydrocephalus. Gene Set Enrichment Analysis (GSEA) (Mootha et al., 2003; Subramanian et al., 2005) was performed by determining enrichment of input genes in the curated gene sets in the
Molecular Signatures Database (MSigDB; http://www.gsea-msigdb.org/gsea/msigdb/index.jsp). This list of input genes was
compared against the MSigDB gene sets (C2: Curated Gene Sets, C5: Gene Ontology, C6: Oncogenic Signature, and C1: Chromosomal location). We used the default options in GSEA/MSigDB (which internally uses the hypergeometric distribution) to perform the
enrichment analysis. Significance of enrichment was assessed using Benjamini-Hochberg adjusted p < 0.05 in each tissue.
Experiment-wide significant gene sets were identified using Bonferroni adjustment (adjusted p < 0.05, which corresponded to
p < 4.1x10 7) based on the total number of gene sets (4,762 curated sets; 5,917 GO sets; 326 chromosomal locations; and 189 oncogenic signatures; total count = 11,194) and the total number of tissues (n = 11).
BioVU analysis of hydrocephalus-related neurological traits
For our experiment-wide significant finding, we considered the PrediXcan associations in the exact discovery tissue (frontal cortex)
with ‘‘Other cerebral degenerations’’ (Phecode: 331; 417 cases and 17,257 controls) and ‘‘Cerebral edema and compression of
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brain’’ (Phecode: 348.2; 635 cases and 17,257 controls) within BioVU to gain further mechanistic insights into the pathogenesis of
hydrocephalus.
UK Biobank replication analysis
Integrated analysis of brain imaging and genomics data can facilitate validation and additional insights into the functional consequences of identified disease-associated genes. We performed PrediXcan analysis in the exact discovery tissue (frontal cortex)
on CSF, white matter, and total brain volumes in the UK Biobank (N = 8,428) to validate our experiment-wide significant finding.
From the T1 MRI structural image and normalized for overall head size, these brain imaging traits had been quantified (Elliott
et al., 2018); we used these phenotypes in the PrediXcan validation analysis. The significance of replication was assessed using Bonferroni-adjusted p < 0.05 based on the total number of gene-tissue-phenotype tuples (1*1*3 = 3) tested. We also tested for enrichment of gene-level associations with these imaging phenotypes among the top differentially expressed genes identified in the frontal
cortex (p < 0.05). In addition, because PrediXcan, the rare-variant exome scan, and a murine model of hydrocephalus appear to
converge on TMEM50B (albeit only nominally), we interrogated the UK Biobank data for the association of the rare variant
rs34327244 (A139T, MAF = 0.4%) within TMEM50B, with Bonferroni-adjusted p < 0.05 (adjusting for the 3 imaging phenotypes)
as the replication significance criterion.
For additional support, we tested the SNPs within the MAEL cis region for association with hydrocephalus (Phenotype code =
G6_HYDROCEPH) in a much larger UK Biobank dataset (N = 361,194, of which 133 are cases). We utilized public association results
from the Benjamin Neale/HAIL team (Bycroft et al., 2018; Ge et al., 2017). Because of the much smaller number of cases than number
of controls in this dataset, we followed a widely used variant quality control (QC) set of recommendations. Out of 10,629 SNPs in the
region, we excluded all low-confidence variants, defined as follows: (a) MAF < 0.10%; (b) 2*(MAF)*(number of cases) < 25. We used
Benjamini-Hochberg adjusted p < 0.05 as the cutoff for significance. We also tested the SNPs within the MAEL cis region (excluding
low-confidence variants) for association with subarachnoid hemorrhage (N = 361,070, of which 124 are cases), a common cause of
hydrocephalus (Germanwala et al., 2010; Graff-Radford et al., 1989).
Differential expression in mice
We leveraged publicly available choroid plexus expression data in mice (GEO: GSE37098), with and without hydrocephalus, on the
C57BL/6J strain to replicate some of our top findings in the two tissues, i.e., frontal cortex and hypothalamus, with significant signals
(Benjamini-Hochberg adjusted p < 0.05 within a tissue) in human patients. Only frontal cortex had an experiment-wide significant
signal, Bonferroni-adjusted p < 0.05 across tested gene-tissue pairs. Gene expression had been previously quantified using Affymetrix Mouse Gene 1.0 ST Array (Robledo et al., 2008). We conducted differential expression analysis using an empirical Bayes method,
as implemented in Linear Models for Microarray Data (limma), to identify gene expression changes associated with hydrocephalus in
these mice. We report the genes that were differentially expressed (p < 0.05) in mice among our top genes (p < 0.05) in human frontal
cortex and hypothalamus (evaluated separately).
Rare variant exome scan
The goal of this analysis was to identify associations between rare exonic variants in genes detected in at least 5 tissues by PrediXcan
and hydrocephalus risk. We developed a cohort of 3,890 children and 25,823 adult patients of European ancestry who had previously
undergone genotyping using Illumina Infinium Human Exome Bead Chip platforms. ICD9 codes for hospital billing were used to algorithmically define cases as well as controls, as previously described (Denny et al., 2013, 2010, Karnes et al., 2017, Wei et al., 2017).
Fisher’s Exact test and Bonferroni correction were used to detect rare variant associations with hydrocephalus (Denny et al., 2013,
2010, Karnes et al., 2017, Simonti et al., 2016). We tested a total of 15 rare variants (i.e., MAF < 1%, including 1 in TMEM50B).
CSF proteomic data from patients with hydrocephalus
We analyzed a proteomic signature consisting of proteins that were found in a mass spectroscopic analysis of CSF (Morales et al.,
2012). We evaluated the genetically determined expression of these genes in frontal cortex for their (PrediXcan) association with hydrocephalus to determine whether the proteins showed significant departure from the null. We then tested whether the signature had
greater statistical significance (i.e., lower p value) than the remaining genes (using Mann-Whitney U test). For the latter, we performed
the comparisons in frontal cortex (the significant discovery tissue) and whole blood (an easily accessible tissue) to further explore the
tissue specificity of these results.
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Figure S1. The most significant SNP (rs75008967, yellow line) within the MAEL cis
region overlaps an enhancer element in fetal brain (male and female) and in several
brain regions (H3K27ac), including prefrontal cortex, based on Roadmap Chip-seq data
(http://www.roadmapepigenomics.org), Related to Figure 4.

Figure S2. Genetically determined associations with neurological disorders for MAEL
interacting partners, Related to Figure 4. (A) STRING analysis revealing MAEL
interaction network derived from various lines of evidence: curated databases (aqua),
experimental determined (pink), gene neighborhood (dark green), gene fusions (red),
gene co-occurrence (dark blue), text mining (light green), co-expression (black), and
protein homology (light blue). The individual proteins shown in the diagram are
predicted functional partners. Interestingly, all proteins shown highlighted here have
some degree of protein structural data. (B) Genetically determined expression
associated with other neurological disorders for proteins in the MAEL interaction
network depicted in (A).
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Figure S3. Top 25 genes across multiple neurological tissues, Related to Figures 3-4.
Gene with nominal association (p<0.05) with hydrocephalus (x-axis) vs. number of
neurological tissues in GTEx (y-axis), demonstrating a small subset of tissue-shared
hydrocephalus-associated genes.
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Figure S4: Exome scan reveals nominally significant rare variant associations in the
most differentially-expressed genes identified by PrediXcan, Related to Figure 4. (A)
Illustration of genetic strategies for elucidating the genetic architecture of disease.
Whole exome sequencing (WES), Exome-Chip based approaches (Rare variant test),
and common-variant associations based on differential gene regulation (PrediXcan) are
used to probe the entire allele frequency spectrum. (B) Exome scan (in a cohort of
29,713 patients of European ancestry) identifies rare variant associations with
hydrocephalus in the most differentially expressed genes across 5 or more neurological
tissues. TMEMB50B is also supported by differential expression (choroid plexus
transcriptome) analysis we performed in a murine model of hydrocephalus. (C)
Correlation between TMEM50B and AQP1 expression in the frontal cortex (Spearman’s
correlation= 0.21, p-value= 0.029), consistent with their effect on hydrocephalus. (D)
Potential mechanism by which TMEM50B may contribute to hydrocephalus
predisposition. TTF1 is a direct transcriptional regulator of the aquaporin 1 (AQP1) in
epithelial cells of the choroid plexus (Kim et al., 2007). rs34327244, identified by the
exome scan, disrupts an enhancer element (marked by H3K4me1) in TMEM50B and a
regulatory motif (Nkx2), leading to increased allelic affinity of TTF1, a direct
transcriptional regulator of AQP1, and thus decreased availability of TTF1 to
promote AQP1 expression.
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Table S1: MAEL SNP predictors of hydrocephalus in the frontal cortex and
hypothalamus, Related to Figure 4.
Frontal Cortex

Hypothalamus

SNP

Weight

rs12081670
rs12742385
rs202253
rs437846
rs12757615
rs1890129
rs2269678
rs4657619
rs561187
rs472293
rs520560
rs517419
rs16858233
rs1890130
rs12124524
rs12731305
rs1845459
rs4656550
rs1120205
rs1120604
rs858557
rs4657563
rs6680946
rs6427065
rs203846
rs500242
rs17344586
rs566841
rs7531189
rs12139875
rs1002160
rs12123839
rs6694465
rs6661553
rs12067635
rs4657621
rs10918372
rs10489192
rs6676134
rs6691431
rs7545806
rs10918603
rs742048
rs6673622
rs11803833
rs1214606
rs2480678
rs4657543
rs17331024
rs10918329
rs402031
rs7538944
rs4657608
rs10489200
rs12141731
rs393025
rs269686
rs269684

-0.163
-0.163
-0.101
-0.094
-0.070
-0.052
-0.049
-0.048
-0.033
-0.029
-0.029
-0.028
-0.028
-0.028
-0.027
-0.027
-0.026
-0.015
-0.013
-0.011
-0.009
-0.008
-0.008
-0.003
-0.002
-0.001
-0.001
-0.001
0.009
0.012
0.013
0.014
0.014
0.014
0.014
0.015
0.015
0.015
0.022
0.035
0.036
0.038
0.038
0.046
0.048
0.055
0.067
0.068
0.073
0.085
0.094
0.103
0.154
0.163
0.169
0.182
0.242
0.284

Reference
allele
T
A
T
G
G
C
T
A
A
T
A
G
T
A
G
G
A
C
T
T
C
G
G
T
T
A
G
T
T
C
C
C
T
A
G
A
A
T
C
T
T
T
G
A
A
G
T
T
A
G
A
C
C
C
C
C
G
C

Effect
Allele
C
G
G
A
A
T
C
G
G
C
G
A
C
G
A
A
G
T
C
C
T
A
T
G
C
G
A
C
C
T
T
T
G
G
A
G
C
C
T
C
C
C
T
G
G
T
G
C
G
A
G
T
T
T
T
A
A
T

SNP

Weight

rs12742385
rs12757615
rs17430677
rs6670426
rs4656560
rs2269673
rs12741275
rs742469
rs34925982
rs3738236
rs520560
rs517419
rs16858233
rs1890130
rs12124524
rs12731305
rs1845459
rs4656550
rs1120205
rs1120604
rs858557
rs4657563
rs6680946
rs6427065
rs203846
rs500242
rs17344586
rs566841
rs7531189
rs12139875
rs1002160
rs12123839
rs6694465
rs6661553
rs12067635
rs4657621
rs10918372
rs10489192
rs6676134
rs6691431
rs7545806
rs10918603
rs742048
rs6673622
rs11803833
rs1214606
rs2480678
rs4657543
rs17331024
rs10918329
rs402031
rs7538944
rs4657608
rs10489200
rs12141731
rs393025
rs269686
rs269684

-0.178
-0.156
-0.132
-0.121
-0.075
-0.075
-0.075
-0.052
-0.050
-0.048
-0.029
-0.028
-0.028
-0.028
-0.027
-0.027
-0.026
-0.015
-0.013
-0.011
-0.009
-0.008
-0.008
-0.003
-0.002
-0.001
-0.001
-0.001
0.009
0.012
0.013
0.014
0.014
0.014
0.014
0.015
0.015
0.015
0.022
0.035
0.036
0.038
0.038
0.046
0.048
0.055
0.067
0.068
0.073
0.085
0.094
0.103
0.154
0.163
0.169
0.182
0.242
0.284

Reference
allele
A
G
T
T
T
G
T
G
A
G
A
G
T
A
G
G
A
C
T
T
C
G
G
T
T
A
G
T
T
C
C
C
T
A
G
A
A
T
C
T
T
T
G
A
A
G
T
T
A
G
A
C
C
C
C
C
G
C

Effect
Allele
G
A
C
C
C
T
C
A
G
A
G
A
C
G
A
A
G
T
C
C
T
A
T
G
C
G
A
C
C
T
T
T
G
G
A
G
C
C
T
C
C
C
T
G
G
T
G
C
G
A
G
T
T
T
T
A
A
T
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Table S2. Replication analysis in the independent UK Biobank, Related to Figure 4-5.
SNPs within the MAEL cis region (within 1 Mb), excluding low-confidence variants (see
Methods), were tested for association with hydrocephalus. We identified 9 variants with
Benjamini-Hochberg FDR<0.05. All 9 variants are common (MAF > 10%) and in linkage
disequilibrium (r2>0.70). The most significant SNP (rs75008967) overlaps an enhancer
element in several brain regions (Figure S1), suggesting regulatory effect.
SNP
rs75008967
rs72695306
rs11810854
rs74796115
rs4330902
rs74119851
rs75065369
rs112620640
rs12410167

Allele 1
A
T
A
G
T
G
C
A
G

Allele 2
C
C
G
A
G
A
T
G
A

P value
0.000352
0.000569
0.000802
0.000827
0.000831
0.000891
0.000924
0.000956
0.000972
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Table S3: Mouse choroid plexus gene expression changes compared to human
imputed gene expression by PrediXcan, Related to Figure 3.

Gene

P value
(human)

Beta
(human)

Tissue

P value
(mice)

-log fold
change
(mice)

t (mice)

TMEM50b

0.016/0.015

-0.728/-0.584

Frontal Cortex &
Hypothalamus

1.14x10-4

3.36x10-1

-4.97

Kctd21

0.040/0.037

-0.365/-0.683

Frontal Cortex &
Hypothalamus

3.02x10-2

1.68x10-1

-2.38

Cry1
Vill
Pkd2
Alg8
Calm2
Sqle
Usp14
Eif2d
Mdh1b
Chchd1
Gas6
Ano10
Fam171b
Usp42
Sfpq
Lrrfip2

0.005
0.010
0.013
0.016
0.018
0.023
0.023
0.038
0.041
0.042
0.030
0.003
0.044
0.021
0.010
0.046

0.754
0.467
0.880
-0.752
10.68
-0.307
-0.734
-0.612
-0.390
-0.155
-0.490
0.491
-1.546
0.551
12.24
0.848

Frontal Cortex
Frontal Cortex
Frontal Cortex
Frontal Cortex
Frontal Cortex
Frontal Cortex
Frontal Cortex
Frontal Cortex
Frontal Cortex
Frontal Cortex
Hypothalamus
Hypothalamus
Hypothalamus
Hypothalamus
Hypothalamus
Hypothalamus

6.94x10-4
4.82x10-2
2.47x10-2
9.56x10-4
7.07x10-3
5.37x10-3
1.00x10-2
4.61x10-2
2.04x10-4
2.34x10-2
2.40x10-3
2.88x10-3
5.40x10-3
1.95x10-2
1.99x10-2
4.88x10-2

-4.35x10-1
-1.46x10-1
-1.42x10-1
3.01x10-1
-1.47x10-1
3.37x10-1
1.72x10-1
-1.03x10-1
5.31x10-1
1.31x10-1
2.18x10-1
-1.99x10-1
7.44x10-3
-1.74x10-1
-1.69x10-1
-1.38x10-1

4.21
2.14
2.48
-4.05
3.10
-3.23
-2.93
2.17
-4.18
-2.51
-3.61
3.53
-3.07
2.60
2.59
2.14
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Supplemental Table S4. Number of subjects and phenotypes included in this study,
Related to Figure 1.

Data source and phenotype
BioVU (PheCode: 331.1, Hydrocephalus)
UK Biobank Hydrocephalus GWAS (G6_HYDROCEPH)
UK Biobank Brain Imaging GWAS
Human cerebrospinal fluid (CSF) proteomic analysis
Mouse choroid plexus microarray information

Number of subjects
N= 19,027, of which 287
are cases
N= 361,194, of which
133 are cases
N= 8,428
N= 12 cases
N= 12, of which 6
developed
hydrocephalus

Discovery or
validation?
Discovery
Validation
Validation
Validation
Validation
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